> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Issues Ajinomoto Bio-Pharma 3-item 483
- URL: https://www.fdaweb.com/fda-issues-ajinomoto-bio-pharma-3-item-483/
- Published: 2023-05-05T12:00:00.000Z
- Updated: 2026-09-14T18:29:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154383

FDA has issued San Diego-based Ajinomoto Bio-Pharma Services a three-item Form FDA-483 after inspecting the firm in January and citing GMP deficiencies. For example, the inspection form says the firm’s quality oversight of validation activities is inadequate. It also cited its facility and equipment maintenance as being deficient to support GMP production activities. Additionally, the 483 said the “responsibilities and procedures applicable to the quality control unit are not fully followed.” To view the 483, click [here](https://www.fda.gov/media/167466/download?ref=fdaweb.com).